- Home
- ESNT vs SBFM Comparison
ESNT vs SBFM Comparison
Compare ESNT & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- SBFM
- Stock Information
- Founded
- ESNT 2008
- SBFM 2006
- Country
- ESNT Bermuda
- SBFM United States
- Employees
- ESNT N/A
- SBFM N/A
- Industry
- ESNT Property-Casualty Insurers
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ESNT Finance
- SBFM Health Care
- Exchange
- ESNT Nasdaq
- SBFM Nasdaq
- Market Cap
- ESNT N/A
- SBFM 4.9M
- IPO Year
- ESNT 2013
- SBFM N/A
- Fundamental
- Price
- ESNT $55.95
- SBFM $1.44
- Analyst Decision
- ESNT Buy
- SBFM Strong Buy
- Analyst Count
- ESNT 7
- SBFM 1
- Target Price
- ESNT $61.71
- SBFM $15.00
- AVG Volume (30 Days)
- ESNT 755.8K
- SBFM 4.4M
- Earning Date
- ESNT 05-09-2025
- SBFM 05-19-2025
- Dividend Yield
- ESNT 2.23%
- SBFM N/A
- EPS Growth
- ESNT 5.38
- SBFM N/A
- EPS
- ESNT 6.85
- SBFM N/A
- Revenue
- ESNT $1,242,904,000.00
- SBFM $34,874,283.00
- Revenue This Year
- ESNT $4.19
- SBFM $192.48
- Revenue Next Year
- ESNT $4.79
- SBFM N/A
- P/E Ratio
- ESNT $8.13
- SBFM N/A
- Revenue Growth
- ESNT 12.00
- SBFM 44.75
- 52 Week Low
- ESNT $51.61
- SBFM $1.17
- 52 Week High
- ESNT $65.33
- SBFM $33.60
- Technical
- Relative Strength Index (RSI)
- ESNT 51.62
- SBFM 40.53
- Support Level
- ESNT $55.11
- SBFM $1.17
- Resistance Level
- ESNT $56.85
- SBFM $1.59
- Average True Range (ATR)
- ESNT 1.69
- SBFM 0.17
- MACD
- ESNT 0.13
- SBFM 0.04
- Stochastic Oscillator
- ESNT 82.82
- SBFM 56.34
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.